Qingdao Haier Biomedical Co Ltd Total Liabilities
Qingdao Haier Biomedical Co Ltd total liabilities. Based on the latest financial reports, Qingdao Haier Biomedical Co Ltd (688139) has total liabilities worth CN¥1.16 Billion CNY (≈ $169.35 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 688139 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Qingdao Haier Biomedical Co Ltd (2016–2025)
Total liabilities of Qingdao Haier Biomedical Co Ltd from 2016 to 2025. This chart illustrates how Qingdao Haier Biomedical Co Ltd's total liabilities have evolved over time, based on quarterly financial data.
Qingdao Haier Biomedical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Qingdao Haier Biomedical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Punjab & Sind Bank
NSE:PSB
|
India | Rs1.67 Trillion |
|
Tongyu Heavy Industry
SHE:300185
|
China | CN¥7.74 Billion |
|
CEAT Limited
NSE:CEATLTD
|
India | Rs88.48 Billion |
|
China Cinda Asset Management Co., Ltd.
F:0CI
|
Germany | €1.50 Trillion |
|
Savaria Corporation
TO:SIS
|
Canada | CA$458.82 Million |
|
Vaisala Oyj A
HE:VAIAS
|
Finland | €270.30 Million |
|
Sichuan Jiuzhou Electronic Co Ltd
SHE:000801
|
China | CN¥4.05 Billion |
|
China Camc Engineering Co Ltd
SHE:002051
|
China | CN¥12.77 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Qingdao Haier Biomedical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Qingdao Haier Biomedical Co Ltd assets under control.
Liquidity & Leverage Metrics
Qingdao Haier Biomedical Co Ltd Total Liabilities Ratios Explained
Qingdao Haier Biomedical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Qingdao Haier Biomedical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Qingdao Haier Biomedical Co Ltd (2016–2025)
The table below shows the annual total liabilities of Qingdao Haier Biomedical Co Ltd from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.17 Billion ≈ $170.96 Million |
-0.09% |
| 2024-12-31 | CN¥1.17 Billion ≈ $171.11 Million |
+7.70% |
| 2023-12-31 | CN¥1.09 Billion ≈ $158.87 Million |
-19.02% |
| 2022-12-31 | CN¥1.34 Billion ≈ $196.18 Million |
+6.31% |
| 2021-12-31 | CN¥1.26 Billion ≈ $184.54 Million |
+8.89% |
| 2020-12-31 | CN¥1.16 Billion ≈ $169.46 Million |
+99.30% |
| 2019-12-31 | CN¥581.08 Million ≈ $85.03 Million |
-47.84% |
| 2018-12-31 | CN¥1.11 Billion ≈ $163.01 Million |
+93.43% |
| 2017-12-31 | CN¥575.92 Million ≈ $84.28 Million |
+154.31% |
| 2016-12-31 | CN¥226.46 Million ≈ $33.14 Million |
-- |
About Qingdao Haier Biomedical Co Ltd
Qingdao Haier Biomedical Co.,Ltd engages in the research and development, manufacture, marketing, and sale of low temperature storage equipment for biomedical samples in China and internationally. The company offers ULT freezers, pharmacy refrigerators, freezers, automatic storage solutions, cryogenics, active temperature controlled RKN containers, and RTMD products; and CO2 incubation, standard … Read more